CLINICAL COMPARISON OF FIRST-LINE PLATIN CHEMOTHERAPY REGIMENS IN PATIENTS WITH ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) USING GERMAN REGISTRY DATA

被引：3
|
作者：
Haas, J. S. [1 ]
Meise, D. [1 ]
Ogbonnaya, A. [2 ]
Braun, S. [1 ]
Eaddy, M. [3 ]
Daessler, K. [4 ]
Sandner, R. [5 ]
Binninger, A. [6 ]
Jaenicke, M. [6 ]
Chiabudini, M. [6 ]
Marschner, N. [7 ]
机构：
[1] Xcenda GmbH, Hannover, Germany
[2] Xcenda LLC, Sci Consulting, Palm Harbor, FL USA
[3] Xcenda LLC, Palm Harbor, FL USA
[4] Onkol Schwerpunktpraxis, Freital, Germany
[5] Gemeinschaftspraxis Dr Prenninger & Dr Sandner, Passau, Germany
[6] iOMEDICO AG, Freiburg, Germany
[7] Praxis Interdisziplinare Onkol & Hamatol, Freiburg, Germany
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
10.1016/j.jval.2017.08.112
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN30
引用
收藏
页码：A416 / A417
页数：2
相关论文
共 50 条
  • [31] Oxaliplatin and docetaxel as first line chemotherapy for patients with non-small cell lung cancer (NSCLC).
    Santos, ES
    Raez, LE
    Rocha-Lima, C
    Tolba, K
    Negret, L
    Farfan, N
    Decesare, T
    Lopes, G
    Rosado, MF
    Wu, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 687S - 687S
  • [32] Biweekly docetaxel and gemcitabine as first line chemotherapy in advanced non-small cell lung cancer (NSCLC)
    Gaspar, E.
    Firvida, J.
    Amenedo, M.
    Orts, D.
    Salgado, M.
    LLorca, C.
    Ramos, M.
    Perez, E.
    Cervera, J.
    Abal, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [33] A Clinical Prognostic Score to Predict Survival of Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients Receiving First-Line Chemotherapy: A Retrospective Analysis
    Gong, Jing
    Xu, Ling
    Li, Zhi
    Hu, Xuejun
    Liu, Jing
    Teng, Yuee
    Jin, Bo
    Zhao, Mingfang
    Shi, Jing
    Guo, Tianshu
    Shi, Xiaonan
    Cheng, Yu
    Liu, Yunpeng
    Qu, Xiujuan
    MEDICAL SCIENCE MONITOR, 2018, 24 : 8264 - 8271
  • [34] Serum Mass-Spectrometry Test in First-Line Advanced Non-Small Cell Lung Cancer Patients Treated with Standard Chemotherapy Regimens
    Grossi, Francesco
    Genova, Carlo
    Rijavec, Erika
    Dal Bello, Maria Giovanna
    Barletta, Giulia
    Biello, Federica
    Maggioni, Claudia
    Grigorieva, Julia
    Meyer, Krista
    Roder, Heinrich
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S540 - S541
  • [35] Nutritional status changes in patients with advanced non-small cell lung cancer receiving first-line chemotherapy
    Wei Sun
    Shunfang Liu
    Ping Peng
    Dongbo Liu
    OncologyandTranslationalMedicine, 2018, 4 (02) : 54 - 57
  • [36] COST-EFFECTIVENESS OF FIRST-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Yang, M. C.
    Tan, E. C. H.
    VALUE IN HEALTH, 2014, 17 (07) : A736 - A736
  • [37] Costs associated with neutropenia in elderly patients treated first-line for advanced non-small cell lung cancer (NSCLC)
    Stokes, M. E.
    Muehlenbein, C. E.
    Marciniak, M. D.
    Faries, D.
    Motabar, S.
    Buesching, D. P.
    Gillespie, T. W.
    Lipscomb, J.
    Knopf, K. B.
    VALUE IN HEALTH, 2008, 11 (03) : A10 - A10
  • [38] Efficacy and Biomarker Data From BEYOND: A Randomized Phase 3 Study of First-Line Chemotherapy ± Bevacizumab in Chinese Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer
    Zhou, C.
    Wu, Y.
    Chen, G.
    Liu, X.
    Zhu, Y.
    Lu, S.
    Feng, J.
    He, J.
    Han, B.
    Wang, J.
    Jiang, G.
    Hu, C.
    Zhang, H.
    Cheng, G.
    Song, X.
    Lu, Y.
    Pan, H.
    Zheng, W.
    Yin, A.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S17 - S17
  • [39] Cost-Effectiveness of Pemetrexed as First-Line Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer
    Klein, Robert
    Wielage, Ron
    Muehlenbein, Catherine
    Liepa, Astra M.
    Babineaux, Steve
    Lawson, Anthony
    Schwartzberg, Lee
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (08) : 1263 - 1272
  • [40] Chemotherapy for advanced non-small cell lung cancer (NSCLC)
    Manegold, C
    LUNG CANCER, 2002, 38 : S47 - S50
12345